Vitamin D Deficiency and Rheumatoid Arthritis

Autor(es):Mostrar menos -

Watanabe Ishikawa, larissa Lumi ^[1] ; Colavite, Priscila Maria ^[1] ; de Campos Fraga-Silva, Thais Fernanda ^[1] ; Nishiyama Mimura, Luiza Ayumi ^[1] ; Donega Franca, Thais Graziela ^[1] ; Goncalves Zorzella-Pezavento, Sofia Fernanda ^[1] ; Chiuso-Minicucci, Fernanda ^[1] ; Marcolino, Larissa Doddi ^[2] ; Penitenti, Marcimara ^[3] ; Valerio Ikoma, Maura Rosane ^[3] ; Sartori, Alexandrina ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Inst Biosci Botucatu, Dept Microbiol & Immunol, Sao Paulo - Brazil

^[2] Botucatu Med Sch, Dept Pathol, Sao Paulo - Brazil

^[3] Amaral Carvalho Fdn, Flow Cytometry Lab, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY; v. 52, n. 3, p. 373-388, JUN 2017.
• Citações Web of Science: 19

Resumo

Vitamin D (VitD) is a hormone primarily synthesized in human skin under the stimulation of ultraviolet radiation. Beyond its endocrine role in bone metabolism, VitD is endowed with remarkable immunomodulatory properties. The effects of VitD on the immune system include the enhancement of microbicidal ability of monocytes/macrophages and the down-modulation of inflammatory cytokines produced by T lymphocytes. VitD deficiency is involved in many health problems, including immune-mediated diseases such as autoimmune disorders. Rheumatoid arthritis (RA) is a chronic inflammatory systemic autoimmune disease that compromises the joints, causing cartilage destruction and bone erosion. RA treatment usually consists of combined therapies that generally suppress the entire immune response leading to increased susceptibility to infections. This review describes the main effects of VitD on innate and adaptive immune system and also VitD status in inflammatory rheumatic diseases such as RA. Despite some controversies, the majority of reports reinforce the idea that lower VitD levels correlate with more severe clinical manifestations in RA and other rheumatic diseases. Therefore, supplementation with VitD to achieve normal serum levels is worthwhile as an aforethought. Original data concerning the potential applicability of 1,25-dihydroxyvitamin D-3 (VitD3), the active form of vitamin D, as a tolerogenic adjuvant are also included. In this sense, the effect of VitD3 associated with proteoglycan (PG), which is a specific cartilage antigen, was tested in the course of experimental arthritis. This association significantly lowered clinical scores and local histopathological alterations. Even though local analysis of T cell subsets and cytokine production did not reveal any difference between the experimental groups, VitD3+PG association significantly reduced cytokine production by spleen cells. These results suggest that VitD3 played a role as a tolerogenic adjuvant by down-modulating the course of experimental RA. Considering this tolerogenic effect of VitD3+PG association, further investigations will reveal its plausible use in human RA. (AU)

• Processo FAPESP: 10/20470-3 - Estratégias tolerogênicas antígeno-específicas visando profilaxia e terapia na artrite autoimune experimental.
• Beneficiário: Larissa Lumi Watanabe Ishikawa
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 11/17325-4 - Estratégias imunomoduladoras na artrite experimental baseadas na indução de tolerância específica por vitamina D3 e rapamicina
• Beneficiário: Alexandrina Sartori
• Modalidade de apoio: Auxílio à Pesquisa - Regular